A no-reflow prediction model in patients with ST-elevation acute myocardial infarction and primary drug-eluting
Chang-Hua Wang1, Yun-Dai Chen, Xin-Chun Yang
1Department of Cardiology, Chinese PLA General Hospital, Beijing, China. wch1201@126.com
Insights
This study identified key predictors of no-reflow in ST-elevation myocardial infarction (STEMI) patients undergoing primary stenting. Factors like age, reperfusion time, and glucose levels significantly influence no-reflow occurrence.
Area of Science:
- Cardiology
- Interventional Cardiology
- Acute Myocardial Infarction Research
Background:
- No-reflow phenomenon is a critical complication following primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
- Understanding independent predictors of no-reflow is crucial for optimizing treatment strategies and improving patient outcomes in current interventional practices.
Purpose of the Study:
- To identify and analyze independent predictors of the no-reflow phenomenon in patients with STEMI.
- To evaluate the association of various clinical, angiographic, and procedural factors with no-reflow after primary drug-eluting stenting.
Main Methods:
- A cohort of 1413 STEMI patients treated with primary drug-eluting stenting within 12 hours of infarction was analyzed.
- Clinical, angiographic, and procedural data were collected, and univariate and multivariate logistic regression models were employed to determine independent predictors of no-reflow.
Main Results:
- No-reflow occurred in 21% of patients (297 out of 1413).
- Independent predictors identified include older age (>65 years), longer time-to-reperfusion (>6 hours), elevated admission plasma glucose (>13.0 mmol/L), poor collateral circulation (0-1), high pre-PCI thrombus score (≥4), and intra-aortic balloon pump (IABP) use.
- A significant positive correlation was observed between the number of identified predictors and the no-reflow rate.
Conclusions:
- A predictive model incorporating six independent factors for no-reflow in STEMI patients undergoing primary stenting has been established.
- Further validation of this prediction model in large-scale prospective studies is recommended to confirm its clinical utility.
Objectives:
This study was undertaken to assess independent no-reflow predictors in patients with ST-elevation acute myocardial infarction (STEMI) and primary drug-eluting stenting in the current interventional strategies.
Design:
One thousand four hundred and thirteen patients with STEMI were successfully treated with primary drug-eluting stenting within 12 h after AMI. All clinical, angiographic and procedural data were collected. Univariate and multivariate logistic regression was used to identify independent no-reflow predictors.
Results:
The no-reflow was found in 297 (21%) of 1413 patients. Univariate and multivariate logistic regression identified that age (>65 years, OR 1.47, 95% CI 1.46-1.49; p = 0.007), long time-to-reperfusion (>6 h, OR 1.27, 95% CI 1.16-1.40; p = 0.001), admission plasma glucose (>13.0 mmol/L, OR 1.27, 95% CI 1.16-1.40; p = 0.027), collateral circulation (0-1, OR 1.69, 95% CI 1.25-2.29; p = 0.001), pre-PCI thrombus score (≥4, OR 1.36, 95% CI 1.16-1.79; p = 0.011), and IABP use before PCI (OR 2.89, 95% CI 1.65-5.05; p < 0.0001) were independent no-reflow predictors. The no-reflow rate significantly increased as the number of independent predictors increased (0%, 6%, 15%, 25%, 40%, 50% and 100% in patients with 0, 1, 2, 3, 4, 5, and 6 independent predictors, respectively; p < 0.0001).
Conclusions:
The prediction model consisted of six no-reflow predictors in patients with STEMI and primary drug-eluting stenting and should be confirmed in large-scale prospective studies.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:28Acute Coronary Syndrome IV: Interprofessional Care